CD109 and squamous cell carcinoma

Squamous cell carcinoma (SCC) is well-known for its high rate of metastasis with poor prognosis. CD109 is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein. Recently, CD109 emerges as a potential biomarker and a therapeutic target for SCCs. Accumulating studies have reported that CD1...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Ruixia, Dong, Fengyun, Liu, Qiang, Murakumo, Yoshiki, Liu, Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889571/
https://www.ncbi.nlm.nih.gov/pubmed/29625613
http://dx.doi.org/10.1186/s12967-018-1461-3
_version_ 1783312724992720896
author Qi, Ruixia
Dong, Fengyun
Liu, Qiang
Murakumo, Yoshiki
Liu, Ju
author_facet Qi, Ruixia
Dong, Fengyun
Liu, Qiang
Murakumo, Yoshiki
Liu, Ju
author_sort Qi, Ruixia
collection PubMed
description Squamous cell carcinoma (SCC) is well-known for its high rate of metastasis with poor prognosis. CD109 is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein. Recently, CD109 emerges as a potential biomarker and a therapeutic target for SCCs. Accumulating studies have reported that CD109 is highly expressed in human SCCs of multiple organs, and may contribute to the progression of SCCs. In this review, we summarized the findings on expression pattern of CD109 in SCCs, and discussed the molecular mechanisms underlying the roles of CD109 in pathogenesis of SCCs.
format Online
Article
Text
id pubmed-5889571
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58895712018-04-10 CD109 and squamous cell carcinoma Qi, Ruixia Dong, Fengyun Liu, Qiang Murakumo, Yoshiki Liu, Ju J Transl Med Review Squamous cell carcinoma (SCC) is well-known for its high rate of metastasis with poor prognosis. CD109 is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein. Recently, CD109 emerges as a potential biomarker and a therapeutic target for SCCs. Accumulating studies have reported that CD109 is highly expressed in human SCCs of multiple organs, and may contribute to the progression of SCCs. In this review, we summarized the findings on expression pattern of CD109 in SCCs, and discussed the molecular mechanisms underlying the roles of CD109 in pathogenesis of SCCs. BioMed Central 2018-04-06 /pmc/articles/PMC5889571/ /pubmed/29625613 http://dx.doi.org/10.1186/s12967-018-1461-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Qi, Ruixia
Dong, Fengyun
Liu, Qiang
Murakumo, Yoshiki
Liu, Ju
CD109 and squamous cell carcinoma
title CD109 and squamous cell carcinoma
title_full CD109 and squamous cell carcinoma
title_fullStr CD109 and squamous cell carcinoma
title_full_unstemmed CD109 and squamous cell carcinoma
title_short CD109 and squamous cell carcinoma
title_sort cd109 and squamous cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889571/
https://www.ncbi.nlm.nih.gov/pubmed/29625613
http://dx.doi.org/10.1186/s12967-018-1461-3
work_keys_str_mv AT qiruixia cd109andsquamouscellcarcinoma
AT dongfengyun cd109andsquamouscellcarcinoma
AT liuqiang cd109andsquamouscellcarcinoma
AT murakumoyoshiki cd109andsquamouscellcarcinoma
AT liuju cd109andsquamouscellcarcinoma

Ejemplares similares